Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1. (Currently Amended) A method of enhancing expression of a desired protein at mucosal effector sites, said method comprising placing a nucleotide sequence encoding the protein to be expressed under the control of a promoter having ~~a nucleotide sequence of SED ID NO 2,~~ the nucleotide sequence of SEQ ID NO: 2 in a construct, which is administered to mucosal cells ~~and causing expression in mucosal cells~~.

2-22. Cancelled.

23. (Currently Amended) The method of claim 1, wherein the ~~promoter is operatively interconnected with a nucleic acid which encodes a protein, able to induce~~ desired protein induces a protective immune response against a pathogen~~,~~ in a mammal to which ~~it~~ the protein is administered.

24. (Currently Amended) The method of claim 1, wherein the ~~nucleotide sequence encoding the protein to be expressed under the control of a promoter having a nucleotide sequence of SEQ ID NO: 2 is contained in~~ construct is transformed into a recombinant gut-colonising microorganism.

25. (Currently Amended) The method of claim 24, wherein the desired protein is heterologous to the recombinant gut-colonising microorganism.

26. (Previously Presented) The method of claim 24, wherein the recombinant gut-colonising microorganism is a *Salmonella spp.*

27. (Currently Amended) The method of claim 26, wherein the ~~*Salmonella Spp*~~ *Salmonella spp.* is *Salmonella typhimurium* or *Salmonella typhi.*

28. (Previously Presented) The method of claim 24, wherein the recombinant gut-colonising microorganism is attenuated.

29. (Previously Presented) The method of claim 23, wherein the protein is able to induce a protective immune response against *Yersinia pestis.*

30. (Currently Amended) The method of claim 29, wherein the protein comprises ~~an~~ the F1-antigen of *Yersinia pestis.*

31. (Previously Presented) The method of claim 24, wherein the recombinant gut-colonising microorganism is administered as a composition which further comprises a pharmaceutically acceptable carrier or diluent.

32. (Previously Presented) The method of claim 31, wherein the composition is adapted for oral administration.